Your session is about to expire
← Back to Search
Radiation Therapy
Stereotactic Radioablation for Ventricular Tachycardia (STAR VTM Trial)
N/A
Recruiting
Led By Vikas Kuriachan, MD
Research Sponsored by University of Calgary
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
18 years of age and have an implanted cardioverter defibrillator (ICD) with structural heart disease: ischemic or non-ischemic cardiomyopathy diagnosed with cardiac imaging demonstrating either segmental myocardial dysfunction, or presence of scar.
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 6 month period before treatment to the 6 month period after ablation with a 6 week blanking period post-treatment.
Awards & highlights
STAR VTM Trial Summary
This trial demonstrates that STAR ablation is a safe and feasible option for cardiomyopathy patients with refractory ventricular tachycardia.
Who is the study for?
This trial is for adults over 18 with an implanted cardioverter defibrillator and structural heart disease, who have experienced certain types of rapid heartbeat (ventricular tachycardia) despite previous treatments. It's not suitable for pregnant individuals, those unable to consent, people who've had radiotherapy in the same area before, or patients with severe heart failure.Check my eligibility
What is being tested?
The trial is testing Stereotactic Arrhythmia Radioablation (STAR), a procedure using targeted radiation to manage refractory ventricular tachycardia in patients with cardiomyopathy. STAR uses cardiac imaging and standard ECGs without needing complex equipment.See study design
What are the potential side effects?
Potential side effects may include skin reactions at the treatment site, fatigue, chest discomfort or pain due to inflammation of surrounding tissues. There might also be risks associated with radiation exposure such as damage to nearby organs.
STAR VTM Trial Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowSelect...
I am 18 or older with an ICD and diagnosed heart disease shown by imaging.
STAR VTM Trial Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ six months
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~six months
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Primary outcome measures
Efficacy of radiation treatment for VT reduction
Safety composite endpoint of radiation treatment-related pericarditis, pneumonitis, changes in cardiac structures, function, and/or ICD function.
Secondary outcome measures
Overall mortality
STAR VTM Trial Design
1Treatment groups
Experimental Treatment
Group I: Radioablation TreatmentExperimental Treatment1 Intervention
Patients will receive radioablation to scar regions of the heart responsible for ventricular tachycardia
Find a Location
Who is running the clinical trial?
University of CalgaryLead Sponsor
792 Previous Clinical Trials
869,134 Total Patients Enrolled
Libin Cardiovascular Institute of AlbertaOTHER
3 Previous Clinical Trials
628 Total Patients Enrolled
Vikas Kuriachan, MDPrincipal InvestigatorUniversity of Calgary
Media Library
Eligibility Criteria:
This trial includes the following eligibility criteria:- I have severe heart failure or need medication that makes it unsafe for me to go to the radiotherapy area.I have had radiation therapy in the area where I will be treated.I have had multiple specific heart rhythm issues despite treatment.I am 18 or older with an ICD and diagnosed heart disease shown by imaging.I cannot or do not want to give my consent for participation.I have had heart-related chest pain in the last 30 days.My heart condition only includes specific types of irregular heartbeats.
Research Study Groups:
This trial has the following groups:- Group 1: Radioablation Treatment
Awards:
This trial has 1 awards, including:- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
Timeline:
This trial has the following timeline:- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
How many subjects are being monitored for this clinical trial?
"Affirmative, the information hosted on clinicaltrials.gov confirms that this experiment is currently enrolling participants. This trial was first posted on April 14th 2021 and updated most recently November 13th 2022. It plans to admit a total of 20 subjects from one site."
Answered by AI
Are additional participants still being admitted for this clinical trial?
"Affirmative. According to the clinicaltrials.gov database, this medical trial is still seeking participants and was initially posted on April 14th 2021 with a latest update recorded on November 13th 2022. It requires 20 patients from 1 site in particular to take part."
Answered by AI
Other Trials to Consider
Popular Categories
Share this study with friends
Copy Link
Messenger